TMPRSS2 inhibitors against prostate cancer metastasis (EvolVeritas)

N/A

Report date: 2025/04/30 09:58:08

Base Information

Drug NameTMPRSS2 inhibitors against prostate cancer metastasis (EvolVeritas)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTransmembrane protease serine 2 inhibitors
TargetsTransmembrane protease serine 2
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHungary
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEvolVeritas Biotechnology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEvolVeritas Biotechnology Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A